Artelo Biosciences Faces Delisting Notice

Ticker: ARTL · Form: 8-K · Filed: May 23, 2025 · CIK: 1621221

Sentiment: bearish

Topics: delisting, listing-standards, regulatory

Related Tickers: ARTL

TL;DR

ARTL might get delisted, major red flag.

AI Summary

Artelo Biosciences, Inc. filed an 8-K on May 23, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, previously known as Reactive Medical Inc. and Knight Knox Development Corp., is incorporated in Nevada and has its principal executive offices in Solana Beach, California.

Why It Matters

This filing indicates potential issues with Artelo Biosciences' continued listing on an exchange, which could significantly impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

FAQ

What specific rule or standard has Artelo Biosciences failed to satisfy, leading to this delisting notice?

The filing does not specify the exact rule or standard that Artelo Biosciences has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is May 22, 2025.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted on May 23, 2025.

What were Artelo Biosciences' previous company names?

Artelo Biosciences, Inc. was formerly known as REACTIVE MEDICAL INC. and KNIGHT KNOX DEVELOPMENT CORP.

In which U.S. state is Artelo Biosciences, Inc. incorporated?

Artelo Biosciences, Inc. is incorporated in Nevada.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 regarding ARTELO BIOSCIENCES, INC. (ARTL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing